Keyword: Bristol-Myers Squibb
Merck & Co. has priced Keytruda at about $2,600 per vial in China, about a 50% discount compared to its U.S. tag.
NICE said yes to Novartis’ Tafinlar and Mekinist in adjuvant melanoma, giving the company a head start over rival BMS.
The U.K. cost watchdog says it doesn't have the PD-1's overall survival data to assess its cost-effectiveness.
England's cost watchdog has decided Merck’s blockbuster Keytruda is not a good treatment choice in Hodgkin lymphoma—at least not for all patients.
Bristol-Myers Squibb has picked its new commercial chief—and the person who'll be charged with maximizing Opdivo's potential.
Opdivo is priced in China at half its U.S. cost; Novartis names new chief for scandal-hit Korea unit; GSK's Indian consumer unit attracts new buyers.
BMS and Pfizer’s Eliquis and J&J and Bayer’s Xarelto will lead the pack in 2024, followed by Amgen’s Repatha, Novartis’ Entresto and J&J's Uptravi.
Thanks to a boost from U.S. regulators, Bristol-Myers Squibb and AbbVie’s Empliciti could have a new indication by the end of the year.